loading page

Children’s Oncology Group’s 2023 Blueprint for Research: Cellular Therapy and Stem Cell Transplantation
  • +6
  • Carrie Kitko,
  • Catherine Bollard,
  • Mitchell Cairo,
  • Joseph Chewning,
  • Terry J. Fry,
  • Michael A. Pulsipher,
  • Shalini Shenoy,
  • Donna Wall,
  • John Levine
Carrie Kitko
Vanderbilt University Medical Center

Corresponding Author:[email protected]

Author Profile
Catherine Bollard
Children's National Hospital
Author Profile
Mitchell Cairo
New York Medical College School of Health Sciences and Practice
Author Profile
Joseph Chewning
The University of Alabama at Birmingham Division of Hematology and Oncology
Author Profile
Terry J. Fry
University of Colorado Anschutz Medical Campus Department of Pediatrics
Author Profile
Michael A. Pulsipher
Primary Children's Hospital
Author Profile
Shalini Shenoy
Washington University in St Louis Washington University Physicians
Author Profile
Donna Wall
The Hospital for Sick Children
Author Profile
John Levine
Icahn School of Medicine at Mount Sinai Tisch Cancer Institute
Author Profile


Since the publication of the last Cellular Therapy and Stem Cell Transplant blueprint in 2013, Children’s Oncology Group cellular therapy-based trials for advanced the field and created new standards of care across a wide spectrum of pediatric cancer diagnoses. Key findings include that tandem autologous transplant improved survival for patients with neuroblastoma and atypical teratoid/rhabdoid brain tumors, one umbilical cord blood (UCB) donor was safer than two UCB donors, killer immunoglobulin receptor (KIR) mismatched donors did not improve survival for pediatric acute myeloid leukemia when in vivo T cell depletion is used and the depth of remission as measured by next-generation sequencing based minimal residual disease assessment pre-transplant was the best predictor of relapse for acute lymphoblastic leukemia. Plans for the next decade include optimizing donor selection for transplants for acute leukemia/myelodysplastic syndrome, using novel engineered cellular therapies to target a wide array of malignancies, and developing better treatments for cellular therapy toxicities such as viral infections and graft-vs-host disease.
03 Jul 2023Submitted to Pediatric Blood & Cancer
03 Jul 2023Assigned to Editor
03 Jul 2023Submission Checks Completed
06 Jul 2023Review(s) Completed, Editorial Evaluation Pending
06 Jul 2023Editorial Decision: Accept